References
- Wang D, Hu B, Hu C, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA. 2020;323(11):1061.
- Li Q, Guan X, Wu P, et al. Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia. N Engl J Med. 2020;382(13):1199–1207.
- Muller MP, McGeer A, Straus SE, et al. Clinical trials and novel pathogens: lessons learned from SARS. Emerging Infect Dis. 2004;10(3):389–394.
- Smith RD. Responding to global infectious disease outbreaks: lessons from SARS on the role of risk perception, communication and management. Soc Sci Med. 2006;63(12):3113–3123.
- Holshue ML, DeBolt C, Lindquist S, et al. First case of 2019 novel coronavirus in the United States. N Engl J Med. 2020;382(10):929–936.
- Jin X, Pang B, Zhang J, et al. Core outcome set for clinical trials on coronavirus disease 2019 (COS-COVID). Engineering. 2020. DOI:10.1016/j.eng.2020.03.002.
- International Association of Antimicrobial Chemotherapy (ISAC) [Internet]. [cited 2020 Apr 3]. Available from: https://www.isac.world/news-and-publications/official-isac-statement
- London AJ, Kimmelman J. Against pandemic research exceptionalism. Science. 2020;368(6490):476–477.
- Wang Y, Zhang D, Du G, et al. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet. 2020;395(10236):1569–1578.